Butyrate, a new microbiota-dependent player in CD8+ T cells immunity and cancer therapy?
Authors:
Open Access
- 1 July 2021
- journal article
- research article
- Published by Elsevier in Cell Reports Medicine
- Vol. 2 (7) , 100328
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunityCell Metabolism, 2021
- Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patientsScience, 2021
- Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patientsScience, 2021
- The Gut Microbiota at the Service of ImmunometabolismCell Metabolism, 2020
- Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer TumorsJAMA Network Open, 2020
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patientsScience, 2018
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumorsScience, 2018
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patientsScience, 2018
- Anticancer effects of the microbiome and its productsNature Reviews Microbiology, 2017
- T-cell–based Immunotherapy: Adoptive Cell Transfer and Checkpoint InhibitionCancer Immunology Research, 2015